** Brokerage BofA Global Research raises PT on drugmaker AbbVie ABBV.N to $223 from $200, a 5.4% upside to the stock's last close
** Maintains "neutral" rating
** PT raise in part due to ABBV signing a licensing deal earlier this week with Danish biotech Gubra GUBRA.CO to develop an obesity treatment that mimics pancreatic hormone amylin
** Brokerage says ABBV expects weight-loss of 15% to 20% as a stand-alone product with better tolerability and less lean-muscle loss than GLP-1 drugs
** Although late-entrants into the obesity drug market could struggle to compete with incumbents Novo Nordisk NOVOb.CO and Eli Lilly LLY.N, a suite of products and/or differentiation will help, BofA says
** Stock has risen 18.2% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.